Routine

Type 2 diabetes mellitus

Endocrine · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Progressive hyperglycaemia from insulin resistance and beta-cell failure, strongly linked to obesity and (in South Asians) central adiposity at lower BMI. Management now prioritises cardiovascular and renal protection alongside glucose control.

Red flags

  • Admit: HHS, DKA (uncommon), severe infection/sepsis, diabetic foot with ischaemia/spreading infection
  • Refer: suspected T1DM/MODY, pregnancy/preconception, renal decline, uncontrolled despite triple therapy, recurrent severe hypos

Assessment

Investigations

  • HbA1c (confirm diagnosis and track), fasting lipids, U&E and eGFR, urine ACR, LFTs
  • Annual: retinal screening, foot exam, ACR
  • Exclude secondary causes if atypical;
  • GAD/anti-IA2 antibodies and C-peptide if T1DM/LADA suspected

Management

  • Lifestyle + metformin first line
  • Add SGLT2 inhibitor (empagliflozin/dapagliflozin) if CVD, heart failure or CKD
  • GLP-1 RA (semaglutide, dulaglutide) if high CV risk or obesity
  • Then DPP-4i, pioglitazone, sulfonylurea; insulin when oral agents inadequate
  • BP target <140/90 (<130/80 if ACR raised), statin per QRISK, atorvastatin 20mg primary prevention

Disposition

Admit: HHS, DKA (uncommon), severe infection/sepsis, diabetic foot with ischaemia/spreading infection.

Complications & pitfalls

  • Microvascular: retinopathy, nephropathy, neuropathy, diabetic foot
  • Macrovascular: MI, stroke, peripheral arterial disease
  • Acute: HHS, hypoglycaemia (treatment-related)
  • Erectile dysfunction, increased infection risk

Exam pearls

  • Start an SGLT2 inhibitor for heart failure or CKD even when HbA1c is at target; the benefit is largely glucose- independent. In South Asians, screen at lower BMI thresholds (overweight >=23 kg/m2).
  • Monitoring & follow-up: HbA1c 3-6 monthly until stable then 6-monthly; individualise target (48-58 mmol/mol). Annual retinal screening, foot risk assessment, urine ACR, eGFR, lipids, BP. Review drug adherence, hypo awareness, injection sites.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.